Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy.

Abstract

Monoclonal antibodies against an estrogen-regulated Mr 24,000 cytosol protein (p24) were used for immunocytochemical localization of p24 in formalin-fixed paraffin-embedded specimens from the primary tumor in 103 patients who received endocrine therapy for advanced breast cancer. Sixty-one per cent of the tumors showed p24-positive staining, and this correlated well with the presence of estrogen receptor (ER) (P = 0.00017, chi-square test). Response to endocrine therapy was obtained in 43% of the patients. A statistically significant association between p24 status and response could not be established, while response and ER status were highly correlated (P = 0.0000029, chi-square = 21.6). Discrimination between ER-positive responders and ER-positive non-responders was not possible using p24 staining.

• Authors: J Andersen, H Skovbon, H S Poulsen
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 25 Issue 4 Pg. 641-3 (Apr 1989) ISSN: 0277-5379 [Print] England
• PMID: 2714341 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• HSP27 Heat-Shock Proteins
• HSPB1 protein, human
• Heat-Shock Proteins
• Molecular Chaperones
• Neoplasm Proteins
• Receptors, Estrogen
• estrogen regulated protein
• Tamoxifen

Topics

• Breast Neoplasms (analysis, therapy)
• Female
• HSP27 Heat-Shock Proteins
• Heat-Shock Proteins
• Humans
• Molecular Chaperones
• Neoplasm Proteins (analysis)
• Ovariectomy
• Receptors, Estrogen (analysis)
• Tamoxifen (therapeutic use)